Association analysis of NAD(P)Hratioquinone oxidoreductase (NQO1) Pro187Ser genetic polymorphism and tardive dyskinesia in patients with schizophrenia in Taiwan.

@article{Liou2005AssociationAO,
  title={Association analysis of NAD(P)Hratioquinone oxidoreductase (NQO1) Pro187Ser genetic polymorphism and tardive dyskinesia in patients with schizophrenia in Taiwan.},
  author={Ying-Jay Liou and Ying-Chieh Wang and Chao-Cheng Lin and Ya-Mei Bai and I-Ching Lai and Ding-Lieh Liao and Jen-Yeu Chen},
  journal={The international journal of neuropsychopharmacology},
  year={2005},
  volume={8 3},
  pages={
          483-6
        }
}
We read with interest a recent study by Pae and colleagues (Pae et al., 2004) regarding a genetic polymorphism Pro187Ser on the NAD(P)H:quinone oxidoreductase ( NQO1 ) gene being associated with tardive dyskinesia (TD). TD is an irregular, non-rhythmic involuntary movement disorder following long-term antipsychotic treatment. Although the pathogenesis of TD is not completely understood, one of the main hypotheses has been focused on neurodegeneration and cell damage in basal ganglia due to the… 

Tables from this paper

No association between a functional NAD(P)H
TLDR
The results suggest that the NQO1 gene polymorphism does not confer an increased risk of TD and is not a good candidate gene that may confer increased susceptibility to TD.
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research
TLDR
Key findings are the association between drug metabolic polymorphisms, mainly in cytochrome P450 genes, with variations in drug metabolic rates and side effects, and the influence of a 5-HT2C polymorphism in antipsychotic-induced weight gain.
Gene Association Studies of Schizophrenia and Tardive Dyskinesia
  • C. Zai
  • Psychology, Biology
  • 2008
TLDR
This analysis investigated the GABAA receptor γ2 subunit gene GABRG2, the dopamine receptor gene DRD3, and the Brain-derived neurotrophic factor gene BDNF that is required for D3 expression by genotyping polymorphisms spanning and surrounding these genes for association with SCZ, as well as suicidal behaviour.
[Pharmacogenetic-based risk assessment of antipsychotic-induced extrapyramidal symptoms].
TLDR
Although there were numerous studies, the pharmacogenetic-based prevention of EPS before prescribing of antipsychotic-induced EPS was not introduced, it is possible to distinguish the most perspectives markers for further research, but only preliminary results were published.
Pharmacogenetics of Response to Antipsychotics in Patients with Schizophrenia
TLDR
Pharmacogenetic studies support the role of cytochrome P450 enzymes and dopamine receptor variants in the development of antipsychotic-induced movement disorders, with a contribution of serotonergic receptors and other gene variants implicated in the mechanism of action of antippsychotics.
...
1
2
3
...

References

SHOWING 1-10 OF 12 REFERENCES
NAD(P)H: quinone oxidoreductase (NQO1) gene polymorphism and schizophrenia
Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia.
TLDR
This study suggests that the NQO1 gene polymorphism (609C/T) may confer susceptibility to the development of TD in schizophrenia, at least in the Korean population.
Oxidative Mechanisms and Tardive Dyskinesia
TLDR
Because evidence has continued to accumulate for increased oxidative damage from antipsychotic medications, but less so for the effectiveness of vitamin E, especially in cases of long-standing tardive dyskinesia, alternative antioxidant approaches to the condition may be warranted.
Drug treatment of Parkinson's disease
  • A. Korczyn
  • Psychology, Medicine
    Dialogues in clinical neuroscience
  • 2004
TLDR
The big void in the therapy of PD lies in the more advanced stages, where several motor symptoms, like postural instability, dysphagia, and dysphonia, as well as dyskinesias, are poorly controlled by existing drugs.
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.
TLDR
Results from 11 long-term studies support the idea that second- generation antipsychotics have a reduced risk for tardive dyskinesia, compared to first-generation antipsychotic, although the doses of haloperidol used in the comparator studies were relatively high.
Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E.
TLDR
These studies suggest that free radicals are probably involved in the pathogenesis of tardive dyskinesia and that vitamin E could be efficacious in its treatment.
Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
TLDR
Risperidone, 6 mg/day, can improve tardive dyskinesia more significantly than discontinuing antipsychotics in patients with severe tardives dysKinesia, especially in the orofacial areas.
...
1
2
...